InflaRx is a young biotech­nol­ogy com­pany with the goal of devel­op­ing anti­bod­ies for ther­a­peu­tic use in inflam­ma­tory dis­eases. The research focus is in the area of acute life-threat­en­ing inflam­ma­tion (use in inten­sive care units) and is cur­rently being expanded to chronic inflam­ma­tory dis­eases and autoim­mune dis­eases. The lead­ing prod­uct can­di­date (IFX‑1) is in the so-called clin­i­cal phase II test­ing on patients.